Novo Nordisk A/S (NONOF)
| Previous close | 126.26 |
| Open | 129.23 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 126.28 - 130.00 |
| 52-week range | 74.70 - 140.32 |
| Volume | |
| Avg. volume | 43,456 |
| Market cap | 567.762B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 48.26 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.86 (1.45%) |
| Ex-dividend date | 22 Mar 2024 |
| 1y target est | N/A |
- Reuters
About 3.6 mln Medicare beneficiaries could be eligible for Wegovy coverage, study shows
About 3.6 million overweight or obese patients with heart conditions insured under the U.S. Medicare program could be eligible for coverage of Novo Nordisk's weight-loss drug Wegovy, a study published by Kaiser Family Foundation (KFF) showed on Wednesday. Wegovy was approved by the U.S. health regulator last month for lowering the risk of stroke and heart attack in overweight or obese adults who do not have diabetes.
- Zacks
Novo Nordisk (NVO) Boasts Earnings & Price Momentum: Should You Buy?
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
- Yahoo Finance Video
Weight loss drugs and the many use cases in medical treatments
Novo Nordisk's (NVO) Ozempic and Wegouvy and Eli Lilly's (LLY) Zepbound are the leading names in the latest GLP-1 weight loss drug cycle, a trend that has seen a variety of use cases sprout up since these brand names' inceptions late last year. Yahoo Finance Health Reporter Anjalee Khemlani explains the new use cases being found for this class of drugs, including infertility treatments and even benefits for Alzheimer's patients. For more expert insight and the latest market action, click here to watch this full episode. This post was written by Luke Carberry Mogan.
